



Homolog Recombination Deficiency, Genetics in Ovarian Cancer

Guest Editor:

Prof. Dr. Amit Manulal Oza

University Health Network
University of Toronto, Toronto,
Canada

Deadline for manuscript
submissions:

closed (30 June 2021)

Message from the Guest Editor

Dear Colleagues,

Contemporary ovarian cancer management incorporates comprehensive approaches to BRCA1/2 and genomic testing to identify the potential for inherited risk (and hence prevention for family members) as well as prediction of therapeutic outcome, most notably with PARP inhibitors. Emerging research on resistance mechanisms will help to guide the potential for future precision therapy to overcome this, or at least avoid futile therapy. This Special Issue will go beyond examining the role of BRCA1/2 and HRD in ovarian cancer and delve into key areas of development in preclinical and clinical domains. Current research is being conducted to advance precise therapeutic approaches (surgical, radiation, and drug development), disease monitoring technologies, equitable access to testing, and therapeutic access to agents such as PARPi and to identify issues related to the impact of treatment chronicity on quality of life.

Prof. Dr. Amit Manulal Oza
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)